Pediatric Praziquantel Consortium

EDCTP and GHIT Fund co-fund the development of a pediatric formulation for schistosomiasis

08 December 2017

Today, the European & Developing Countries Clinical Trials Partnership (EDCTP) and The Global Health Innovative Technology Fund (GHIT) announced that they will be co-funding the phase III clinical study conducted by the Pediatric Praziquantel Consortium. 

Pediatric Praziquantel Consortium to present development program at Swiss TPH Winter symposium and GHIT R&D Forum

01 December 2017

Dr Elly Kourany-Lefoll (Program Lead) and Dr Remco de Vrueh (Consortium coordinator) will participate as invited speakers at the Swiss TPH Winter symposium in Basel and GHIT R&D Forum in Tokyo, respectively. 

A story of schistosomiasis infection in Ghana

A story of schistosomiasis infection in Ghana. 
Video credit: Shelly Xie

 

Vision

Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more

Mission

Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

Soon after its formation, the consortium established a pediatric drug development program, divided into two major steps: preclinical development, and clinical development.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. This formulation that aims to use small, orally dispersible tablets with an acceptable taste. 

Read more